Loading
A phase 1/2 trial of AK119, Ivonescimab, CAPOX in colorectal cancer, run by Akeso, active and no longer recruiting.
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer is a phase 1/2 interventional study registered as NCT05846867 by Akeso, with 170 participants planned, started 2023-05-08 and due to reach its primary completion in 2026-05-08. Interventions recorded: AK119, AK112, Oxaliplatin, Irinotecan, Calcium folinate. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Akeso, Ivonescimab, FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin).
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
Shares Akeso, Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.